Wooed by State Spending, Russian Drugmaker Bets on Brazil The Moscow Times The Biocad facility will produce the cancer-fighting trastuzumab, as well as pegylated interferon against rheumatoid arthritis, and rituximab to combat hepatitis type C. Last year, the Brazilian government spent about $200 million toward acquiring ... |
